Quality of life (QoL) and toxicity in patients (pts) with hormone receptor-positive, HER2-negative early breast cancer (HR+, HER2-eBC) treated with adjuvant (adj) endocrine therapy (ET) in the CANcer TOxicities (CANTO) study

被引：0
|
作者：
Bertaut, A. [1 ]
Crnjevic, T. Badovinac [2 ]
Martin, A-L. [3 ]
Gaudin, C. [4 ]
Chen, L. [5 ]
机构：
[1] Ctr Georges Francois Leclerc Canc Ctr, Methodol & Biostat Unit, Dijon, France
[2] F Hoffmann La Roche AG Switzerland, Clin Sci Oncol, Basel, Switzerland
[3] Unicancer, Hlth Data & Partnership Dept, Paris, France
[4] Unicancer, Canc Tox CANTO, Paris, France
[5] Genentech Inc, Prod Dev Data Sci RWD Enabling Platform, South San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1075
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
346P
引用
收藏
页码：S320 / S321
页数：2
相关论文
共 50 条
  • [1] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [2] Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2-EBC)
    Bardia, Aditya
    Schmid, Peter
    Harbeck, Nadia
    Rimawi, Mothaffar F.
    Hurvitz, Sara A.
    Loi, Sherene
    Saji, Shigehira
    Jung, Kyung Hae
    Werutsky, Gustavo
    Stroyakovskii, Daniil
    Lopez-Valverde, Vanesa
    Tesarowski, David
    Ye, Chenglin
    Davis, Michael
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Geyer, Charles E., Jr.
    CANCER RESEARCH, 2022, 82 (04)
  • [3] Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer
    Yayoi Adachi
    Isao Oze
    Masataka Sawaki
    Masaya Hattori
    Akiyo Yoshimura
    Haruru Kotani
    Ayumi Kataoka
    Kayoko Sugino
    Nanae Horisawa
    Yuri Ozaki
    Yuka Endo
    Kazuki Nozawa
    Daiki Takatsuka
    Hiroji Iwata
    Breast Cancer, 2021, 28 : 1087 - 1095
  • [4] Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer
    Adachi, Yayoi
    Oze, Isao
    Sawaki, Masataka
    Hattori, Masaya
    Yoshimura, Akiyo
    Kotani, Haruru
    Kataoka, Ayumi
    Sugino, Kayoko
    Horisawa, Nanae
    Ozaki, Yuri
    Endo, Yuka
    Nozawa, Kazuki
    Takatsuka, Daiki
    Iwata, Hiroji
    BREAST CANCER, 2021, 28 (05) : 1087 - 1095
  • [5] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
  • [7] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [8] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [9] lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician's choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2-eBC)
    Geyer, Charles
    Bardia, Aditya
    Harbeck, Nadia
    Rimawi, Mothaffar F.
    Hurvitz, Sara A.
    Martin, Miguel
    Loi, Sherene
    Saji, Shigehira
    Jung, Kyung Hae
    Werutsky, Gustavo
    Stroyakovskiy, Daniil
    Lopez-Valverde, Vanesa
    Davis, Michael
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Kawasaki, Junji
    Koi, Yumiko
    Akiyoshi, Sayuri
    Koga, Chinami
    Tokunaga, Eriko
    CANCER RESEARCH, 2024, 84 (09)
12345